Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Mar;13(1):71-81.
doi: 10.1007/s11864-011-0180-2.

mTOR inhibitors and its role in the treatment of head and neck squamous cell carcinoma

Shaun A Nguyen  1 , David Walker, M Boyd Gillespie, J Silvio Gutkind, Terry A Day
Affiliations
Review

mTOR inhibitors and its role in the treatment of head and neck squamous cell carcinoma

Shaun A Nguyen et al. Curr Treat Options Oncol. 2012 Mar.

Abstract

Head and neck squamous cell carcinomas (HNSCC) represent 6% of all cancers diagnosed each year in the United States, affecting approximately 43,000 new patients and resulting in approximately 12,000 deaths. Currently, three main rapalogs exist for the treatment of cancer: CCI-779 (temsirolimus), RAD001 (everolimus), and AP235373 (deforolimus). Clinicians managing HNSCC need to be aware of the three rapalogs. Extensive evidence has shown rapamycin-analogs to be effective agents in the treatment of a number of solid tumors. While extensive preclinical data suggests that HNSCC would be an appropriate tumor type to benefit from inhibition of the mTOR pathway, limited clinical data is yet available to support this. Numerous phase II trials evaluating mTOR inhibitors for use in HNSCC are currently recruiting patients.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Oncogene. 2000 Dec 27;19(56):6680-6 - PubMed
    1. Cancer Res. 2011 Nov 15;71(22):7103-12 - PubMed
    1. Ann Oncol. 2005 Apr;16(4):525-37 - PubMed
    1. Nat Cell Biol. 2004 Nov;6(11):1122-8 - PubMed
    1. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4029-37 - PubMed

MeSH terms

LinkOut - more resources